SpringWorks Therapeutics Stock Gets A RS Rating Lift

The Relative Strength (RS) Rating for SpringWorks Therapeutics (SWTX) stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.

↑ X NOW PLAYING This Is How 2025 Jobs Reports Will Impact The Fed And Rate Cuts

This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.

Decades of market research reveals that the market's biggest winners tend to have an RS Rating of above 80 as they begin their largest price moves. See if SpringWorks Therapeutics stock can continue to rebound and hit that benchmark.

When To Sell Stocks To Lock In Profits And Minimize Losses

Is SpringWorks Therapeutics Stock A Buy?

SpringWorks Therapeutics stock recently reclaimed its 50-day moving average and not in a proper buying range. See if the biotech stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.

The biotech company reported 0% EPS growth in the latest quarterly report. Revenue increased 0%.

SpringWorks Therapeutics stock holds the No. 79 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics (ADMA), Exelixis (EXEL) and Halozyme Therapeutics (HALO) are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."

YOU MAY ALSO LIKE:

Learn How To Time The Market With IBD's ETF Market Strategy

Find Today's Best Growth Stocks To Watch With IBD 50

Find The Best Long-Term Investments With IBD Long-Term Leaders

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks